Creating a non-invasive test for diagnosing Alzheimer's disease using cell-free mRNA.
Development of cell free messenger RNA-based non-invasive diagnostic biomarker for Alzheimer's Disease
['FUNDING_SBIR_2'] · SUPERFLUID DX, INC. · NIH-10916443
This study is working on a simple blood test that could help doctors diagnose Alzheimer's disease earlier and more easily by looking at specific RNA markers in the blood, making it a friendlier option than current tests that can be costly and invasive.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SUPERFLUID DX, INC. (nih funded) |
| Locations | 1 site (South San Francisco, UNITED STATES) |
| Trial ID | NIH-10916443 on ClinicalTrials.gov |
What this research studies
This research aims to develop a non-invasive diagnostic test for Alzheimer's disease (AD) by analyzing cell-free messenger RNA (cf-mRNA) found in the bloodstream. The approach involves using advanced next-generation sequencing technology to accurately quantify cf-mRNA levels, which may differ significantly between individuals with AD and healthy individuals. By focusing on these biomarkers, the research seeks to provide a more accessible and cost-effective alternative to current diagnostic methods, such as PET scans and cerebrospinal fluid analysis, which can be invasive and expensive. This could greatly benefit patients by allowing for earlier and easier diagnosis of Alzheimer's disease and mild cognitive impairment.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals showing early signs of cognitive impairment or those at risk for developing Alzheimer's disease.
Not a fit: Patients with advanced Alzheimer's disease or other forms of dementia unrelated to Alzheimer's may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a simple blood test that allows for early and accurate diagnosis of Alzheimer's disease.
How similar studies have performed: Other research has shown promise in using cf-mRNA as biomarkers in various diseases, suggesting potential success for this novel approach in Alzheimer's diagnostics.
Where this research is happening
South San Francisco, UNITED STATES
- SUPERFLUID DX, INC. — South San Francisco, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: TODEN, SHUSUKE — SUPERFLUID DX, INC.
- Study coordinator: TODEN, SHUSUKE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease